Bladder Cancer Diagnosis, Treatment, and Prevention May Be Aided by Tumor Suppressor Gene
January 22, 2016
Bladder cancer remains the costliest cancer to treat per capita, taking into account diagnostic testing, management, and long-term follow-up. Continued development of urine-based biomarker diagnostic tests may help replace the costly and more invasive techniques of imaging, cytology, and cystoscopy for cancer detection. Genome-wide expression and sequencing studies have identified genes and pathways considered key drivers of bladder cancer.